Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy

Waleed M. Abuzeid, Xiaoling Jiang, Guoli Shi, Hui Wang, David Paulson, Koji Araki, David Jungreis, James Carney, Bert W. O'Malley, Daqing Li

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Platinum-based drugs that induce DNA damage are commonly used first-line chemotherapy agents for testicular, bladder, head and neck, lung, esophageal, stomach, and ovarian cancers. The inherent resistance of tumors to DNA damage often limits the therapeutic efficacy of these agents, such as cisplatin. An enhanced DNA repair and telomere maintenance response by the Mre11/Rad50/Nbs1 (MRN) complex is critical in driving this chemoresistance. We hypothesized therefore that the targeted impairment of native cellular MRN function could sensitize tumor cells to cisplatin. To test this, we designed what we believe to be a novel dominantnegative adenoviral vector containing a mutant RAD50 gene that significantly downregulated MRN expression and markedly disrupted MRN function in human squamous cell carcinoma cells. A combination of cisplatin and mutant RAD50 therapy produced significant tumor cytotoxicity in vitro, with a corresponding increase in DNA damage and telomere shortening. In cisplatin-resistant human squamous cell cancer xenografts in nude mice, this combination therapy caused dramatic tumor regression with increased apoptosis. Our findings suggest the use of targeted RAD50 disruption as what we believe to be a novel chemosensitizing approach for cancer therapy in the context of chemoresistance. This strategy is potentially applicable to several types of malignant tumors that demonstrate chemoresistance and may positively impact the treatment of these patients.

Original languageEnglish (US)
Pages (from-to)1974-1985
Number of pages12
JournalJournal of Clinical Investigation
Volume119
Issue number7
DOIs
StatePublished - Jul 1 2009
Externally publishedYes

Fingerprint

Cisplatin
Drug Therapy
DNA Damage
Neoplasms
Telomere Shortening
Therapeutics
Squamous Cell Neoplasms
Telomere
Esophageal Neoplasms
Head and Neck Neoplasms
Platinum
Heterografts
Nude Mice
DNA Repair
Ovarian Neoplasms
Stomach Neoplasms
Squamous Cell Carcinoma
Lung Neoplasms
Urinary Bladder
Down-Regulation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. / Abuzeid, Waleed M.; Jiang, Xiaoling; Shi, Guoli; Wang, Hui; Paulson, David; Araki, Koji; Jungreis, David; Carney, James; O'Malley, Bert W.; Li, Daqing.

In: Journal of Clinical Investigation, Vol. 119, No. 7, 01.07.2009, p. 1974-1985.

Research output: Contribution to journalArticle

Abuzeid, WM, Jiang, X, Shi, G, Wang, H, Paulson, D, Araki, K, Jungreis, D, Carney, J, O'Malley, BW & Li, D 2009, 'Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy', Journal of Clinical Investigation, vol. 119, no. 7, pp. 1974-1985. https://doi.org/10.1172/JCI33816
Abuzeid, Waleed M. ; Jiang, Xiaoling ; Shi, Guoli ; Wang, Hui ; Paulson, David ; Araki, Koji ; Jungreis, David ; Carney, James ; O'Malley, Bert W. ; Li, Daqing. / Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy. In: Journal of Clinical Investigation. 2009 ; Vol. 119, No. 7. pp. 1974-1985.
@article{09d9124f046c4fceaec5d09754a64dcb,
title = "Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy",
abstract = "Platinum-based drugs that induce DNA damage are commonly used first-line chemotherapy agents for testicular, bladder, head and neck, lung, esophageal, stomach, and ovarian cancers. The inherent resistance of tumors to DNA damage often limits the therapeutic efficacy of these agents, such as cisplatin. An enhanced DNA repair and telomere maintenance response by the Mre11/Rad50/Nbs1 (MRN) complex is critical in driving this chemoresistance. We hypothesized therefore that the targeted impairment of native cellular MRN function could sensitize tumor cells to cisplatin. To test this, we designed what we believe to be a novel dominantnegative adenoviral vector containing a mutant RAD50 gene that significantly downregulated MRN expression and markedly disrupted MRN function in human squamous cell carcinoma cells. A combination of cisplatin and mutant RAD50 therapy produced significant tumor cytotoxicity in vitro, with a corresponding increase in DNA damage and telomere shortening. In cisplatin-resistant human squamous cell cancer xenografts in nude mice, this combination therapy caused dramatic tumor regression with increased apoptosis. Our findings suggest the use of targeted RAD50 disruption as what we believe to be a novel chemosensitizing approach for cancer therapy in the context of chemoresistance. This strategy is potentially applicable to several types of malignant tumors that demonstrate chemoresistance and may positively impact the treatment of these patients.",
author = "Abuzeid, {Waleed M.} and Xiaoling Jiang and Guoli Shi and Hui Wang and David Paulson and Koji Araki and David Jungreis and James Carney and O'Malley, {Bert W.} and Daqing Li",
year = "2009",
month = "7",
day = "1",
doi = "10.1172/JCI33816",
language = "English (US)",
volume = "119",
pages = "1974--1985",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "7",

}

TY - JOUR

T1 - Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy

AU - Abuzeid, Waleed M.

AU - Jiang, Xiaoling

AU - Shi, Guoli

AU - Wang, Hui

AU - Paulson, David

AU - Araki, Koji

AU - Jungreis, David

AU - Carney, James

AU - O'Malley, Bert W.

AU - Li, Daqing

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Platinum-based drugs that induce DNA damage are commonly used first-line chemotherapy agents for testicular, bladder, head and neck, lung, esophageal, stomach, and ovarian cancers. The inherent resistance of tumors to DNA damage often limits the therapeutic efficacy of these agents, such as cisplatin. An enhanced DNA repair and telomere maintenance response by the Mre11/Rad50/Nbs1 (MRN) complex is critical in driving this chemoresistance. We hypothesized therefore that the targeted impairment of native cellular MRN function could sensitize tumor cells to cisplatin. To test this, we designed what we believe to be a novel dominantnegative adenoviral vector containing a mutant RAD50 gene that significantly downregulated MRN expression and markedly disrupted MRN function in human squamous cell carcinoma cells. A combination of cisplatin and mutant RAD50 therapy produced significant tumor cytotoxicity in vitro, with a corresponding increase in DNA damage and telomere shortening. In cisplatin-resistant human squamous cell cancer xenografts in nude mice, this combination therapy caused dramatic tumor regression with increased apoptosis. Our findings suggest the use of targeted RAD50 disruption as what we believe to be a novel chemosensitizing approach for cancer therapy in the context of chemoresistance. This strategy is potentially applicable to several types of malignant tumors that demonstrate chemoresistance and may positively impact the treatment of these patients.

AB - Platinum-based drugs that induce DNA damage are commonly used first-line chemotherapy agents for testicular, bladder, head and neck, lung, esophageal, stomach, and ovarian cancers. The inherent resistance of tumors to DNA damage often limits the therapeutic efficacy of these agents, such as cisplatin. An enhanced DNA repair and telomere maintenance response by the Mre11/Rad50/Nbs1 (MRN) complex is critical in driving this chemoresistance. We hypothesized therefore that the targeted impairment of native cellular MRN function could sensitize tumor cells to cisplatin. To test this, we designed what we believe to be a novel dominantnegative adenoviral vector containing a mutant RAD50 gene that significantly downregulated MRN expression and markedly disrupted MRN function in human squamous cell carcinoma cells. A combination of cisplatin and mutant RAD50 therapy produced significant tumor cytotoxicity in vitro, with a corresponding increase in DNA damage and telomere shortening. In cisplatin-resistant human squamous cell cancer xenografts in nude mice, this combination therapy caused dramatic tumor regression with increased apoptosis. Our findings suggest the use of targeted RAD50 disruption as what we believe to be a novel chemosensitizing approach for cancer therapy in the context of chemoresistance. This strategy is potentially applicable to several types of malignant tumors that demonstrate chemoresistance and may positively impact the treatment of these patients.

UR - http://www.scopus.com/inward/record.url?scp=68449095987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449095987&partnerID=8YFLogxK

U2 - 10.1172/JCI33816

DO - 10.1172/JCI33816

M3 - Article

VL - 119

SP - 1974

EP - 1985

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 7

ER -